The in vitro activity of GR 20263, a new cephalosporin, was compared primarily with the activities of moxalactam (LY 127935) GR 20263 is a new parenteral aminothiazolyl cephalosporin from Glaxo Group Research which combines stability to a wide range of,-lactamases, a broad antibacterial spectrum, and low toxicity (3) . In this study a wide range of recent clinical isolates were tested gainst GR 20263 and other relevant fi-lactams, in particular cefotaxime (1, 7) and moxalactam, the novel oxa-
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